Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer (NCT06058988)
Window of Opportunity Assessment of [Fam-]Trastuzumab DERuxtecan-nxki (T-DXd) Brain Tumor Penetration and Efficacy (WOnDER-BT)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
📞 Contact the Study Coordinator
Phone: (212) 639-7075
Email: mossn@mskcc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Brain Cancer
- A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma — Los Angeles, California
- Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers — Detroit, Michigan
- Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma — Los Angeles, California
- Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker — Lebanon, New Hampshire
- A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors — New York, New York
- Measuring the Feasibility and Effect of a Virtual Reality Cognitive Training Intervention for Brain Cancer Survivors. — Cincinnati, Ohio
Explore by condition: All Brain Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.